ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Feb. 04, 2025 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

   
DateTotal number of shares

in the capital		Total number of voting rights
01/31/2025100,093,87388,660,571
   

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contacts:       

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980,  

Attachment



EN
04/02/2025

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

Christophe-Raphaël Ganet ... (+2)
  • Christophe-Raphaël Ganet
  • Stephane Beyazian
FRA FRAPORT AG
SZG SALZGITTER AG
MRN MERSEN SA
ALCLS CELLECTIS SA
SDF K+S AG
MIL BANK MILLENNIUM SA
SIX2 SIXT SE
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
KENDR KENDRION NV
TWEKA TKH GROUP N.V. CERT
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
JEN JENOPTIK AG
HGEA HGEARS AG
IOS IONOS GROUP SE
SPG SPRINGER NATURE AG & CO. KGAA
05/13/25 May 13, 2025 1 EN
Christophe-Raphaël Ganet ... (+2)
  • Christophe-Raphaël Ganet
  • Stephane Beyazian
FRA FRAPORT AG
SZG SALZGITTER AG
MRN MERSEN SA
ALCLS CELLECTIS SA
SDF K+S AG
MIL BANK MILLENNIUM SA
SIX2 SIXT SE
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
KENDR KENDRION NV
TWEKA TKH GROUP N.V. CERT
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
JEN JENOPTIK AG
HGEA HGEARS AG
IOS IONOS GROUP SE
SPG SPRINGER NATURE AG & CO. KGAA
05/13/25 May 13, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
05/13/25 May 13, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
05/13/25 May 13, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Reports Financial Results for the First Quarter 2025

Cellectis Reports Financial Results for the First Quarter 2025 Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral gene editing and base editing rese...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch